

## DAFTAR PUSTAKA

1. Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. *Lancet*. 2016;387:1012-24.
2. Edge SB, Greene FI, Byrd DR, Brookland RK, Washington MK, Gersenwald JF, et al. 2016. *AJCC cancer staging manual*. 8<sup>th</sup> ed, p104. Chicago: Springer Nature.
3. Naomi SM, Dewi YA, Agustina H, Naomi SM, Dewi YA, Agustina H. Association between histopathological grading and clinical staging in nasopharyngeal carcinoma. *Journal of Medicine and Health*. 2018;2(2):730-37.
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394-24.
5. Salehiniya H, Mohammadian M, Hafshejani AM, Mahdavifar N. Nasopharyngeal cancer in the world: Epidemiology, incidence, mortality and risk factors. *World Cancer Research Journal*. 2016;5(1): 1-8.
6. Adham M, Gondhowiarjo S, Soediro R, Jack Z, Lisnawati, Witjaksono F, et al. *Pedoman nasional pelayanan kedokteran: Kanker nasofaring*. Kementerian Kesehatan Republik Indonesia. 2017.
7. Melani W, Sofyan F. Karakteristik penderita kanker nasofaring di rumah sakit h. adam malik medan tahun 2011. *E-Jurnal FK-USU*. 2013;1(1):1-5.
8. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in indonesia: Epidemiology, incidence, signs, and symptoms at presentation. *Chinese Journal of Cancer*. 2012;31(4):185-96.
9. Pusat Data dan Informasi Kementerian Kesehatan RI. *Stop kanker: Situasi penyakit kanker*. 2015:hal 1-8.
10. Diniati A, Ade W, Harianto. Distribusi keganasan nasofaring berdasarkan pemeriksaan histopatologi pada rumah sakit di kota pekanbaru tahun 2009-2013. *Jurnal Online Mahasiswa*. 2016;3(1):1-18.
11. Faiza S, Rahman S, Asri A. Karakteristik klinis dan patologis karsinoma nasofaring di bagian THT-KL RSUP DR.M.djamil padang. *Jurnal Kesehatan Andalas*. 2013;5(1):90-6.
12. Adham M, Rohdiana D, Mayangsari ID, Musa Z. Delayed diagnosis of nasopharyngeal carcinoma in a patient with early signs of unilateral ear disorder. *Med J Indones*. 2014;23(1):52-7.
13. Goh J, Lim K. Imaging of nasopharyngeal carcinoma. *Ann Acad Med Singapore*. 2009;38(9):809-16.
14. Alotaibi AD, Ahmed HG, Elsbali AM. Nasopharyngeal cancer in saudi arabia: Epidemiology and possible risk factors. *Journal of Oncological Sciences*. 2019;5(1):23-30.
15. Riedel F, Zaiss I, Herzog D, Götte K, Naim R, Hörmann K. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. *Anticancer Reserach*. 2005;25(5):2761-66.
16. Nikakhlagh S, Ranjbari N, Khorami E, Saki N. Association between serum levels of interleukin-6 and stage of laryngeal cancer. *Iran J*

- Otorhinolaryngol. 2015;27(80):199-205.
17. Sahibzada HA, Khurshid Z, Khan RS, Naseem M, Siddique KM, Mali M, et al. Salivary IL-8, IL-6 and TNF- $\alpha$  as potential diagnostic biomarkers for oral cancer. *Diagnostics*. 2017;7(21):1-10.
  18. Yadav NK, Shukla P, Singh P, Bansode FW, Singh RK. Role of cytokine signalling in head and neck cancers. *International Journal of Basic and Applied Medical Sciences*. 2012;2(2): 101-07.
  19. Bussu F, Graziani C, Gallus R, galli J, Corso ED, Cintio GD, et al. IFN-  $\gamma$  and other serum cytokines in head and neck squamous cell carcinomas. *Acta Otorhinolaryngologica Italica*. 2018: 38; 94-102.
  20. Rajcani J, Banati F, Szenthe K, Niller HH, Minarovits J, Stipkovits L, et al. Detection of interleukin 6 ( IL-6 ) antigen in the head and neck carcinoma cells. *Clinical and Medical Investigations*. 2019;4:1-8.
  21. Tan EL, Selvaratnam G, Kananathan R, Sam CK. Quantification of epstein-barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor- $\beta$ 1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma. *BMC Cancer*. 2006;6(49):1-8.
  22. Li X, Bhaduri-McIntosh S. A central role for STAT-3 in gammaherpesvirus-life cycle and -diseases. *Front Microbiol*. 2016;7:1-10.
  23. Chen H, Hutt-Fletcher L, Cao L, Hayward SD. A positive autoregulatory loop of Imp1 expression and stat activation in epithelial cells latently infected with epstein-barr virus. *Journal of Virology*. 2003;77(7):4139-48.
  24. Pries R, Nitsch S, Wollenberg B. Role of cytokines in head and neck squamous cell carcinoma. *Expert Rev Anticancer*. 2006;6(9):1195-203.
  25. Cottin SC, Turcotte S, Douville P, Meyer F, Bairati I. Predictors of circulating interleukin-6 levels in head and neck cancer patients. *Cancer of the Head & Neck*. 2018;3(1):1-10.
  26. Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT-3 signalling axis in cancer. *Nature Review Clinical Oncology*. 2018;15(4):234-48.
  27. Dahl RA. Targeting interleukin-6 trans-signaling in head and neck squamous cell carcinoma (tesis). Iowa: University of Iowa; 2018.
  28. Huang SCM, Tsao SW, Tsang CM. Interplay of viral infection, host cell factors and tumor microenvironment in the pathogenesis of nasopharyngeal carcinoma. *Cancers*. 2018;10(4): 1-18.
  29. Gourzones C, Barjon C, Busson P. Seminars in cancer biology host – tumor interactions in nasopharyngeal carcinomas. *Seminars in Cancer Biology*. 2012;22(2):127-36.
  30. Lippitz BE. Cytokine patterns in patients with cancer : A systematic review. *Lancet Oncol*. 2013;14(6):e218-e28.
  31. Wah S, Ling Y, Man C, Shin P, mang V, Zhang G, et al. Etiological factors of nasopharyngeal carcinoma. *Oral Oncology*. 2014;50(5):330-38.
  32. Elhabashy H. Applicability of serum interleukin-6 as a screening tool for nasopharyngeal carcinoma. *Journal of American Science*. 2012;8(12):432-39.
  33. Jin Y Bin, Zhang GY, Lin KR, Chen XP, Cui JH, Wang YJ, et al. Changes of plasma cytokines and chemokines expression level in nasopharyngeal carcinoma patients after treatment with definitive intensity-modulated

- radiotherapy (IMRT). PLoS One. 2017;12(2):1-9.
34. Patel VJ, Chen NW, Resto VA. Racial and ethnic disparities in nasopharyngeal cancer survival in the united states. *Otolaryngol - Head Neck Surgery*. 2017;156(1):122-31.
  35. Wee JTS, Ha TC, Loong SLE, Qian CN. Is nasopharyngeal cancer really a “Cantonese cancer”? *Chin J Cancer*. 2010;29(5):517-26.
  36. Kadir A, Retnowati K, Akil MA, Usman AN. The evaluation of serum IL-6 changes as proliferative cytokines in patients with nasopharyngeal carcinoma before and after the ionizing radiotherapy. *Global Journal of Health Science*. 2018;10(8):55-60.
  37. Munir D. Peran gen HLA-DQB1 pada penyebab kerentanan karsinoma nasofaring suku batak. *Majalah Kedokteran Nusantara*. 2010;41(3):185-90.
  38. Noerwidi S. Strategi Adaptasi austronesia di kepulauan indonesia. *Berk Arkeol*. 2009;(1):1-13.
  39. Rahman S. Hubungan DNA virus epstein- barr, alel HLA-DRB1 dan polimorfisme gen CYP2E1 dengan kejadian karsinoma nasofaring pada etnik minangkabau (disertasi) Padang: Fakultas Kedokteran Universitas Andalas;2019.
  40. Sari JTP. Hubungan alel human leukocyte antigen A\*11 dengan kejadian karsinoma nasofaring pada etnik minangkabau di RSUP Dr. M. Djamil Padang (tesis). Padang: Fakultas Kedokteran Universitas Andalas; 2018.
  41. Poh SS, Chua MLK, Wee JTS. Carcinogenesis of nasopharyngeal carcinoma: An alternate hypothetical mechanism. *Experimental Oncology*. 2016;35(1):1-9.
  42. Wei WI, Chua DTT. 2014. Nasopharyngeal carcinoma. Dalam: Newlands S, Amin M, Branstetter B, Casselbrant M, Eibling D, Ferguson B, et al (editor). *Bailey's head & neck surgery*. Edisi ke-5. Philadelphia: Lippincott-Raven Publisher; 2014. hlm. 1875-86.
  43. Jia W, Qin H. Seminars in Cancer Biology Non-viral environmental risk factors for nasopharyngeal carcinoma: A systematic review. *Seminar in Cancer Biology*. 2012;22(2):117-26.
  44. Beigzadeh Z, Pourhassan B, kalantary S, Golbabaei F. Occupational exposure to wood dust and risk of nasopharyngeal cancer: A systematic review and meta-analysis. *Environmental Research*. 2019;(December):170-76.
  45. Umar B, Ahmed R. Nasopharyngeal carcinoma, an analysis of histological subtypes and their association with EBV, a study of 100 cases of Pakistani population. *Asian Journal of Medical Sciences*. 2014;5(4):16-20.
  46. Ho Y, Tsao SW, Zeng M, Lui VWY. STAT-3 as a therapeutic target for Epstein-Barr virus (EBV) - associated nasopharyngeal carcinoma. *Cancer Letters*. 2013;330(2):141-49.
  47. Mu SZ, Yi XZ. Pathogenesis and etiology of nasopharyngeal carcinoma in: *Nasopharyngeal cancer multidisciplinary management*. Springer. 2010:9-25.
  48. Putera I, Ramadhan MG, Anindya S, Sutanto N, Kurniawan A, Hosea N, et al. Relationship between salted fish consumption and nasopharyngeal carcinoma: An evidence-based case report. *Acta Medica Indonesiana*. 2015;47(1):72-7.

49. Lau H, Leung C, Chan Y, Lee AWM, Kwong DLW, Lung ML, et al. Secular trends of salted fish consumption and nasopharyngeal carcinoma : a multi-jurisdiction ecological study in 8 regions from 3 continents. *BMC Cancer*. 2013;13(298):1-11.
50. Polesel J, Franceschi S, Talamini R, Negri E, Barzan L, Montella M, et al. Tobacco smoking, alcohol drinking, and the risk of different histological types of nasopharyngeal cancer in a low-risk population. *Oral Oncology*. 2011;47(6):541-45.
51. Long M, Fu Z, Li P, Nie Z. Cigarette smoking and the risk of nasopharyngeal carcinoma: A meta-analysis of epidemiological studies. *BMJ Open*. 2017;7(10):14-7.
52. Arslan N, Tuzuner A, Koycu A, Dursun S, Hucumenoglu S. The role of nasopharyngeal examination and biopsy in the diagnosis of malignant diseases. *Brazilian Journal of Otorhinolaryngol*. 2018;(xx):1-4
53. Soepardi EA. Pemeriksaan telinga, hidung, tenggorok kepala dan leher. Dalam: Soepardi EA, Iskandar N, Bashiruddin J, Restuti RD, editor. *Buku ajar ilmu kesehatan: telinga, hidung, tenggorok, kepala & leher*. Edisi ke-7. Jakarta: Badan Penerbit FKUI; 2015. hlm. 4.
54. Yamashiro I, De Souza RP. Imaging diagnosis of nasopharyngeal tumors. *Radiol Bras*. 2007;40(1):45-52.
55. Simpson RJ, Hammacher A, Smith DK, Hews JMM, Ward LD. Interleukin-6 : Structure-function relationships. *Protein Science*. 1997;6:929-55.
56. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nature Immunology*. 2015;16(5):448-57.
57. Liao Q, Zeng Z, Guo X, Wei F, Zhang W, Li X, et al. LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the STAT-3 activation. *Oncogene*. 2014;33(16):2098-109.
58. Ke L, Xiang Y, Xia W, Yang J, Yu Y, Ye YF, et al. A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment interleukin 6 and clinical stage. *Clinical Immunology*. 2016;164:45-51.
59. Cao W, Chen X, Lin L, Ma W, Wang D, Zhou L. Associations of serum CD62P and IL-6 levels with nasopharyngeal carcinoma staging and prognosis. *Int J Clin Exp Pathol*. 2016;9(9):9631-35.
60. Miranda HC, Nunes SOV, Reiche EMV, Oda JMM, Watanabe MAE. Higher than normal plasma Interleukin-6 concentrations in brazilian patients with mood disorders. *Brazilian Archives of Biology Technology*. 2011;54(4):717-22.
61. Zergoun A, Zebboudj A, Sellam SL, Kariche N, Djennaoui D, Ouraghi S, et al. IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients. *Tumour Biol*. 2016; 37(3):3505-14.
62. Beer L. Effects of blood sample handling procedures on measured cytokine and chemokine concentrations in human serum and plasma (tesis). Wina. Universitas Kedokteran Wina; 2012.
63. Choy E, Rose-John S. Interleukin-6 as a multifunctional regulator: Inflammation, immune response, and fibrosis. *J Scleroderma Relat Disord*. 2017;2(2):1-5.

64. Gallo O, Gori AM, Attanasio M, Martini, Giusti B, Brunelli, et al. Interleukin-6 and acute-phase proteins in head and neck cancer. *Eur Arch Oto-Rhino-Laryngology*. 1995;252(3):159-62.
65. Gabay C. Interleukin-6 and chronic inflammation. *Arthritis Research & Therapy*. 2006;8(2):1-6.
66. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. *Carcinogenesis*. 2009;30(7):1073-81.
67. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. *Japanese Cancer Association*. 2014;105(1):1-8.
68. Choudhary MM, France TJ, Teknos TN, Kumar P. Interleukin-6 role in head and neck squamous cell carcinoma progression. *World Journal of Otorhinolaryngology Head and Neck Surgery*. 2016;2(2):90-7.
69. Li Z, Zaric B, Tsakiridis K, Zarogoulidis K. Interleukin 6 cytokine: A multifunctional glycoprotein for cancer. *Immunome Res*. 2013;9(62):1-11.
70. Kiprian D, Czarkowska B, Wyczalkowska A, Fuksiewicz M, Kotowicz B, Paczek L. Radiotherapy and radiochemotherapy increase serum levels of pro-inflammatory interleukin-6 and C-reactive protein in patients with head and neck cancers. *Translation Cancer Research*. 2018;7(1):41-7.
71. Toumpanakis D, Vassilakopoulos T. Molecular mechanisms of action of Interleukin-6 (IL-6). *Pneumon*. 2007;2(20):154-67.
72. Kishimoto T. Interleukin-6: Discovery of a pleiotropic cytokine. *Arthritis Research & Therapy*. 2006;8(2): 1-6.
73. Avalle L, Camporeale A, Camperi A, Poli V. Cytokine STAT-3 in cancer : A double edged sword. *Cytokine*. 2017:1-8.
74. Zhang G, Tsang CM, Deng W, Yip YL, Lui VWY, Wong SCC, et al. Enhanced il-6/il-6r signaling promotes growth and malignant properties in ebv-infected premalignant and cancerous nasopharyngeal epithelial cells. *PLoS One*. 2013;8(5):1-13.
75. Johnston PA, Grandis JR. STAT-3 signaling: Anticancer strategies and challenges. *Molecular Interventions*. 2011;11(1):18-26.
76. Sivaraman K, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, et al. Targeting the STAT-3 signaling pathway in cancer : Role of synthetic and natural inhibitors. *Biochimica et Biophysica Acta*. 2014;1845(2):136-54.
77. Stadler ME, Patel MR. Molecular biology of head and neck cancer : Risks and pathways. *Hematol Oncol Clin North Am*. 2008;22:1099-124.
78. Du L, Shen J, Weems A, Lu S. Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma. *Journal of Oncology*. 2012;2012:1-12.
79. Broek R Vander, Mohan S, Eytan DF, Chen Z, Waes C Van. The PI3K / Akt / mTOR axis in head and neck cancer : functions , aberrations , cross-talk , and therapies. *Oral Disease*. 2014;53:1-8.
80. Peng Q, Deng Z, Pan HAO, Gu L, Liu O, Tang Z. Mitogen - activated protein kinase signaling pathway in oral cancer ( Review ). *Oncology Letters*. 2018;15:1379-88.
81. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. *Oncogene*. 2007;26; 3291-310.

82. Cetin I, Cetin A, Sen A, Cimen B, Cimen L, Savas G, et al. Comparison of elisa and flow cytometry for measurement of interleukin-1 beta, interleukin-6 and tumor necrosis factor- $\alpha$ . *Turkish J Biochem*. 2018;43(5):540-48.
83. Chang K, Kao H, Wu C, Fang KH, Chang YL, Huang YC, et al. Pretreatment interleukin-6 serum levels are associated with patient survival for oral cavity squamous cell carcinoma. *Otolaryngology-Head and Neck Surgery*. 2013;148(5): 786-91.
84. Boster. Elisa fundamental principle, How elisa works. (Diunduh 16 September 2019). Tersedia dari: URL: Hyperlink: <https://www.bosterbio.com/protocol-and-troubleshooting/elisa-principle>.
85. Rusling JF, Kumar C V, Silvio J, Patel V. Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. *Analyst*. 2010; 135: 2496-511.
86. Sudoyo AW. Kanker kolorektal usia muda etnik jawa, sunda, makassar , dan minang di Indonesia : Kajian klinikopatologi dan imunohistokimia instabilitas mikrosatelit (disertasi). Jakarta: Fakultas Kedokteran Universitas Indonesia; 2005.
87. Naim A, Syaputra H. Kewarganegaraan, suku bangsa, agama dan bahasa sehari-hari penduduk indonesia. Jakarta: Badan Pusat Statistik; 2010.
88. Madiyono B, Moeslichan S, Sastroasmoro S, Budiman I, Purwanto SH. Perkiraan besar sampel: Dalam: Sastroasmoro S, Ismael S, editor. *Dasar-dasar metodologi penelitian klinis*. Edisi ke-5. Jakarta: Sagung Seto; 2014. hlm 352-87.
89. Yong SK, Ha TC, Yeo MCR, Gaborieau V, McKay JD, Wee J. Associations of lifestyle and diet with the risk of nasopharyngeal carcinoma in Singapore: A case-control study. *Chinese Journal of Cancer*. 2017;36(1):3-10.
90. Tang LL, Chen WQ, Xue WQ, He YQ, Zheng RS, Zeng YX, et al. Global trends in incidence and mortality of nasopharyngeal carcinoma. *Cancer Letters*. 2016;374(1):22-30.
91. Xie SH, Yu ITS, Tse LA, Mang OWK, Yue L. Sex difference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983-2008: Suggestion of a potential protective role of oestrogen. *European Journal of Cancer*. 2013;49(1):150-55.
92. Rahman S. Clinical presentation of nasopharyngeal carcinoma in west sumatera , indonesia. *Proceeding of the 20<sup>th</sup> International Federation of oto-Rhino- Laryngology Societies (IFOS)*; 2013 June 1-5; Seoul, South Korea. Research Gate; 2013.
93. Zhu Y, Song X, Li R, Quan H, Yan L. Assessment of nasopharyngeal cancer in young patients aged  $\leq 30$  Years. *Frontiers in Oncology*. 2019;9:1-8.
94. Chang ET, Liu Z, Hildesheim A, Liu Q, Cai Y, Zhang Z, et al. Active and passive smoking and risk of nasopharyngeal carcinoma: A population-based case-control study in southern china. *American Journal of Epidemiology*. 2017;185(12):1272-80.
95. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. *Cancer Cell*. 2001; vol 5:423-28.
96. Turkoz FP, Celenkoglu G, Dogu GG, Kalender ME, Coskun U, Alkis N, et al. Risk factors of nasopharyngeal carcinoma in Turkey - an epidemiological

- survey of the anatolian society of medical oncology. *Asian Pacific Journal of Cancer Prevention*. 2011;12(11):3017-21.
97. Vaughan TL, Stewart P, Teschke K, Lynch CF, Swanson GM, Lyon JL, et al. Nasopharyngeal cancer in a low-risk population: Defining risk factors by histological type. *Cancer Epidemiol Biomarkers Prev*. 1996;5(8):587-93.
  98. Wu L, Li C, Pan L. Nasopharyngeal carcinoma: A review of current updates. *Experimental and Therapeutic Medicine*. 2018;15(4):3687-92.
  99. Jayalie VF, Paramitha MS, Jessica J, Liu CA, Ramadianto AS, Trimartani, et al. Profile of nasopharyngeal carcinoma in dr. Cipto Mangunkusumo national hospital, 2010. *eJournal Kedokt Indones*. 2017;4(3):156-62.
  100. Tabuchi K, Nakayama M, Nishimura B, Hayashi K, Hara A. Early detection of nasopharyngeal carcinoma. *Int J Otolaryngol*. 2011:1-6.
  101. Indrasari S, Sudarman K, Fedriani J. The primary tumor and regional lymph node clinical status of distant metastasis in nasopharyngeal carcinoma. *J Otorhinolaryngol Hearing and Balance Medicine*. 2018;1(9):1-7.
  102. Ruan Y, Hu W, Li W, Lu H, Gu H, Zhang Y, et al. Analysis of plasma EBV-DNA and soluble checkpoint proteins in nasopharyngeal carcinoma patients after definitive intensity-modulated radiotherapy. *Biomed Research International*. 2019;2019:1-10.
  103. Yeung DCM, Yeung Z, Wong EWY, Vlantis AC, Chan JYK. Neck lymph node status on survival of regionally recurrent or persistent nasopharyngeal carcinoma. *Scientific Reports*. 2020;10(1):1-8.
  104. Zhu Y, Song X, Li R, Quan H, Yan L. Assessment of nasopharyngeal cancer in young patients aged  $\leq 30$  years. *Frontier in Oncology*. 2019;9:1-8.
  105. Zhang G, Tsang CM, Deng W, Yip YL, Lui VWY, Wong SCC, et al. Enhanced il-6/il-6r signaling promotes growth and malignant properties in ebv-infected premalignant and cancerous nasopharyngeal epithelial cells. *PLoS One*. 2013;8(5):1-13.
  106. Soehartono S, Prasetyo MT, Surjotomo H, Yudhanto HS. Korelasi ekspresi IL-6 dengan STAT3 pada metastasis penderita KNF WHO tipe 3 LMP-1 positif. *Oto Rhino Laryngol Indones*. 2019;49(20):152-61.
  107. Grecwin. Perbedaan alel human leucocyte antigen A\*02 antara pasien karsinoma nasofaring dengan kontrol etnik minangkabau (tesis). Padang: Fakultas Kedokteran Universitas Andalas;2018.
  108. Gong Y, Liang S, Zeng L, Ni Y, Zhou S, Yuan X. Effects of blood sample handling procedures on measurable interleukin 6 in plasma and serum. *J Clin Lab Anal*. 2019;33(7):1-7.
  109. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. *Cancer Res*. 2003;63(11):2948-56.
  110. Hoffmann SC, Stanley EM, Cox ED, Dimercurio BS, Koziol DE, Harlan DM, et al. Ethnicity greatly influences cytokine gene polymorphism distribution. *American Journal of Transplantation*. 2002;2(6):560-67.
  111. Gao SP, Liang S, Pan M, Sun RL, Chen C, Luan H, et al. Interleukin-6 genotypes and serum levels in Chinese Hui population. *Int J Clin Exp Med*. 2014;7(9):2851-57.

112. Velez DR, Menon R, Thorsen P, Jiang L, Simhan H, Morgam N, et al. Ethnic differences in interleukin 6 (IL-6) and IL6 receptor genes in spontaneous preterm birth and effects on amniotic fluid protein levels. *Ann Hum Genet.* 2007;71(5):586-600.
113. Charan M, Verma AK, Hussain S, Misri S, Mishra S, Majumder S, et al. Molecular and cellular factors associated with racial disparity in breast cancer. *Int J Mol Sci.* 2020;21(16):1-18.
114. Hayashida H. Effects of the menstrual cycle and acute aerobic exercise on cytokine Levels. *J Sports Med Doping Stud.* 2015;06(01):6-10.
115. Garcia MLA, Soto CM, Guerrero AJA, Aguirre MC, Millan FT, Andrade SI, et al. Low Serum interleukin-6 is a differential marker of obesity-related metabolic dysfunction in women and men. *J Interf Cytokine Res.* 2020;40(3):131-38.
116. Sparano A, Lathers DMR, Achille N, Petruzzelli GJ, Young MRI. Modulation of th1 and th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. *Otolaryngol - Head Neck Surgery.* 2004;131(5):573-76.
117. Messex JK, Byrd CJ, Liou GY. Signaling of macrophages that contours the tumor microenvironment for promoting cancer development. *Cells.* 2020;9(4):1-15.
118. Lotfi A, Shahidi N, Bayazian G, Fakhim SA, Estakhri R, Esfahani A, et al. Serum level of interleukin 6 in patients with oral tongue squamous cell carcinoma. *Irian Journal of Otorhinolaryngology.* 2015;27(3):207-11.
119. Huang YH, Yang HY, Huang SW, Ou G, Hsu YF, Hsu MJ. Interleukin-6 induces vascular endothelial growth factor-C expression via Src-FAK-STAT-3 signaling in lymphatic endothelial cells. *PLoS One.* 2016;11(7):1-18.
120. Islam M, Sharma S, Teknos TN. RhoC regulates cancer stem cells in head and neck squamous cell carcinoma by overexpressing IL-6 and phosphorylation of STAT-3. *PLoS One.* 2014;9(2). 1-11.
121. Yadav A, Kumar B, Datta J, Teknos TN, Kumar P. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the jak-STAT-3-snail signaling pathway. *Molecular Cancer Research.* 2011;9(12):1658-67.
122. Jiang M, Chen J, Zhang W, Zhang R, Ye Y, Liu P, et al. Interleukin-6 trans-signaling pathway promotes immunosuppressive myeloid-derived suppressor cells via suppression of suppressor of cytokine signaling 3 in breast cancer. *Frontier in Immunology.* 2017;8(1840):1-22.
123. Ibrahim SA, El-Ghonaimy EA, Hassan H, Mahana N, Mahmoud MA, Mamlouk TE, et al. Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expression. *Journal of Advanced Research.* 2016;7(5):661-70.
124. Young LS, Dawson CW. Epstein-Barr virus and nasopharyngeal carcinoma. *Chinise Journal of Cancer.* 2014;33(12):581-90.
125. Rzemieniewska GN, Bednarek I. The role of nanog transcriptional factor in the development of malignant phenotype of cancer cells. *Cancer Biology & Therapy.* 2016;17(1):1-10.
126. Hernandez QM, Kuri HW, González RA, Castro MF. Interleukin-6



- promotes human epidermal keratinocyte proliferation and keratin cytoskeleton reorganization in culture. *Cell and Tissue Research*. 2006;325(1):77-90.
127. Knupfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. *Int J Colorectal Dis*. 2010;25(2):135-40.
  128. Waldner MJ, Foersch S, Neurath MF. Interleukin-6 - A key regulator of colorectal cancer development. *International Journal of Biological Sciences*. 2012;8(9):1248-53.
  129. Jarnicki A, Putoczki T, Ernst M. STAT-3: Linking inflammation to epithelial cancer - more than a gut feeling? *Cell Division*. 2010;5:1-15.

